Prognostic Stage IV Breast Cancer AJCC v8 Clinical Trials

56 clinical trials for Prognostic Stage IV Breast Cancer AJCC v8 across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer — RECRUITING · PHASE2
• Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax — RECRUITING · PHASE1
• Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors — RECRUITING · PHASE2
• Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. — RECRUITING · PHASE2
• S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer — RECRUITING · NA
• Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer — RECRUITING · PHASE1
• Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer — RECRUITING · PHASE2
• Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer — RECRUITING · PHASE1
• Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors — RECRUITING
• Paclitaxel Therapeutic Drug Monitoring in Cancer Patients — SUSPENDED
• Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases — TERMINATED · PHASE1
• Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study — ACTIVE_NOT_RECRUITING · PHASE2
• Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival — COMPLETED · PHASE2
• In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring — SUSPENDED
• Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases — ACTIVE_NOT_RECRUITING · PHASE2
• PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery — COMPLETED · PHASE1
• CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer — ACTIVE_NOT_RECRUITING · NA
• Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases — TERMINATED · PHASE1
• Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study — COMPLETED
• Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel — COMPLETED · PHASE2
• T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer — COMPLETED · PHASE1
• Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer — WITHDRAWN · PHASE1
• INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study — ACTIVE_NOT_RECRUITING · PHASE2
• Nipple Aspirate Fluid in Detecting Breast Cancer — COMPLETED · NA
• Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis — COMPLETED · PHASE2
• Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer — COMPLETED · PHASE1
• Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer — COMPLETED · PHASE1
• Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study — TERMINATED · PHASE2
• Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer — WITHDRAWN · PHASE2
• Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer — COMPLETED · PHASE1
• Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer — COMPLETED · PHASE1
• 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases — COMPLETED · PHASE1
• Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer — COMPLETED · PHASE1
• Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy — WITHDRAWN · PHASE2
• Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial — WITHDRAWN · PHASE1
• A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer — WITHDRAWN · PHASE1
• Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer — TERMINATED · PHASE2
• Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice — COMPLETED · NA
• Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer — WITHDRAWN · PHASE1
• SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer — WITHDRAWN · PHASE1
• M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer — TERMINATED · PHASE1
• Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer — WITHDRAWN · NA
• T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer — WITHDRAWN · PHASE2
• Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer — COMPLETED · PHASE1
• Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases — WITHDRAWN · PHASE1

Refine this search